This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PEACE-3 Trial
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
ANKTIVA
Bladder Cancer Detection
CORE-001 Study
ADSTILADRIN
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SCS AUA 2024
ASTRO 2024
IBCN 2024
ESMO 2024
BCAN TT 2024
All Conferences
View All
Quick Takes
ESMO 2024
PCF
UroToday Home
Conference Highlights
ASCO 2024
ASCO 2024 Bladder Cancer
ASCO 2024
Prostate Cancer
Bladder Cancer
Kidney Cancer
Testicular and Penile Cancer
Upper Tract Urothelial Carcinoma
Press Releases
ASCO 2024 Bladder Cancer
Viewing 8961-8980 of 11775 articles
CUA 2017: Outcomes of an Aggressive Biopsy Strategy in Young Men with Prostate-Specific Antigen Between 0.5 and 2.5
CUA 2017: Magnetic Resonance Imaging-Targeted vs. Systematic Biopsies in Men on Active Surveillance: Results of a Prospective, Randomized Canadian Urology Research Consortium Trial
CUA 2017: Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer
CUA 2017: Association Between Germline Genetic Variation and Progression in Men with Low-Risk Prostate Cancer on Active Surveillance
CUA 2017: Prostate-Specific Antigen Levels in Men Aged 60-70 and Development of Lethal Prostate Cancer Over 30 Years: Implications for Risk-Stratified Screening
CUA 2017: Defining a Cohort of Men Who May Not Require Repeat Prostate Biopsy Based on Negative Predictive Value of PCA3 and MRI Combined: The Double-Negative Effect
CUA 2017: Chemotherapy and Novel Hormones in “Low Volume” Hormone-Sensitive Metastatic Prostate Cancer
CUA 2017: Immuno-Oncology Update in Advanced Bladder Cancer
CUA 2017: State of the Art Immunotherapy for Urologic Cancers.
CUA 2017: Update on Bladder Preservation in Muscle Invasive Disease
CUA 2017: PSMA-Targeted Radionuclide Therapies in Treatment of Prostate Cancer
CUA 2017: The Role of Testosterone Nadir Levels in Androgen Deprivation Therapy
CUA 2017: Optimizing Active Surveillance for Prostate Cancer
CUA 2017: Role of MRI in Diagnosing Prostate Cancer
CUA 2017: Role of Androgen Deprivation in Salvage Radiotherapy
CUA 2017: Intraductal Prostate Cancer: Marker of Aggressive Disease?
CUA 2017: Liquid Biopsy in Personalizing CRPC Therapy
TAT-10: Efficacy of Actinium-225-labeled Anti-CD33 Antibody in Acute Myeloid Leukemia Correlates with Peripheral Blast Count
TAT-10: Bi-213-anti-EGFR-Mab Therapy of Recurrent Bladder Cancer - A Pilot Study
TAT-10: Targeted Alpha Therapy of Glioblastoma Multiforme: Clinical Experience with Bi213 and Ac225-Substance P
444
445
446
447
448
449
450
451
452
453
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free